Search

Interdisciplinary approach to CKM care

Explore the global impact of Cardiovascular- Kidney- Metabolic (CKM) syndrome, and the need for an integrated approach to manage these interconnected conditions. Insights from experts at Boehringer Ingelheim and George Washington University.

Classical Swine Fever live vaccine approved in China

Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved

How dangerous is the mpox virus?

Mpox, formerly known as monkeypox: What exactly is this virus, how is it transmitted, and what are the most noticeable symptoms?

EMA filing acceptance and validation for spesolimab

The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis

Cardio-Renal-Metabolic

Cardio-Renal-Metabolic Therapeutic Area

Retinal Health

Human Pharma Clinical Pipeline Retinal Health therapeutic area

Monoclonal antibodies Boehringer Ingelheim and Invetx

Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics

Phase 1 start of treatment for Geographic Atrophy patients

Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)

It is about saving lives Alexis Jaliquias feline blood bank

Veterinarian Alexis Jaliquias founded one of the first blood banks for cats in South America

equine asthma

Fighting Equine Asthma is a crucial step to improving the well-being of many horses worldwide. The right treatment can make a world of difference.

Official partner to Cat Care for Life

Boehringer Ingelheim announces its new partnership with the CatCareforLife program.

Spesolimab (BI 655130): IL36R antibody

Spesolimab (BI 655130): IL36R antibody | PG

Spesolimab (BI 655130): IL36R antibody

U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults

Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults

European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis

Advancing health: Our impactful R&D investments

Discover how we’re investing in sustainable impact with an unwavering commitment to research and development

Vicadrostat (BI 690517) + empagliflozin

PRRS vaccine celebrates 25 years in Europe

Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe

Results for Jardiance EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack

CAROLINA-CARMELINA-Asia-analysis

CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes

The Goals to Improve Living with GPP

An article that describes the current goals to improve the lives of those living with generalized pustular psoriasis

New spesolimab data show significant improvement in GPP flares

Spesolimab prevents GPP flares

Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial

LastMile initiative to address barriers in animal healthcare

The ‘LastMile’ initiative addresses major barriers in animal healthcare sector in Sub-Saharan African

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Interdisciplinary approach to CKM care

Classical Swine Fever live vaccine approved in China

How dangerous is the mpox virus?

EMA filing acceptance and validation for spesolimab

Cardio-Renal-Metabolic

Retinal Health

Monoclonal antibodies Boehringer Ingelheim and Invetx

Phase 1 start of treatment for Geographic Atrophy patients

It is about saving lives Alexis Jaliquias feline blood bank

equine asthma

Official partner to Cat Care for Life

Spesolimab (BI 655130): IL36R antibody

Spesolimab (BI 655130): IL36R antibody | PG

Spesolimab (BI 655130): IL36R antibody

U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults

European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis

Advancing health: Our impactful R&D investments

Vicadrostat (BI 690517) + empagliflozin

PRRS vaccine celebrates 25 years in Europe

Results for Jardiance EMPACT-MI phase III trial

CAROLINA-CARMELINA-Asia-analysis

The Goals to Improve Living with GPP

New spesolimab data show significant improvement in GPP flares

Spesolimab prevents GPP flares

LastMile initiative to address barriers in animal healthcare